Medicare Enrolled
Dr. Devesh Pandya, M.D.
Hematology & Oncology · Houston, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Pandya from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pandya?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Pandya
Dr. Devesh Pandya is a hematology & oncology specialist in Houston, TX, with 18 years of NPI registration. Based on federal Medicare data, Dr. Pandya performed 38,784 Medicare services across 1,322 unique beneficiaries.
Between the years covered by Open Payments, Dr. Pandya received a total of $1,698,245 from 52 pharmaceutical and/or device companies across 1332 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pandya is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 25% volume in TX
$1,698,245 industry payments
Medicare Practice Summary
Medicare Utilization ↗38,784
Medicare services
Top 25% in TX for hematology & oncology
1,322
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,155 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
25,500 | $0 | $2 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
8,350 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,000 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 930 | $1 | $4 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
908 | $8 | $24 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
371 | $90 | $393 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
181 | $132 | $557 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
151 | $22 | $90 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
151 | $7 | $36 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
135 | $99 | $414 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
122 | $8 | $10 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
119 | $11 | $51 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
118 | $12 | $53 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
88 | $46 | $204 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
82 | $16 | $72 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
81 | $59 | $277 |
| Basic blood chemical test (calcium, ionized) A blood test that measures basic chemical levels, specifically including calcium and ionized calcium. |
69 | $13 | $42 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
68 | $58 | $567 |
| Blood creatinine level test A blood test that measures the amount of creatinine, a waste product from muscle wear and tear, to help assess kidney function. |
64 | $5 | $16 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
63 | $19 | $89 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
56 | $1,191 | $5,354 |
| New patient office visit, complex (60-74 min) | 53 | $169 | $688 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
47 | $188 | $1,027 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 47 | $101 | $506 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
30 | $120 | $519 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
66.7% high complexity
28.1% medium
5.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,698,245
Total received (2018-2024)
Avg $242,606/year across 7 years
Top 0% in TX for hematology & oncology
52
Companies
1,332
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,665,969 (98.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$29,687 (1.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,588 (0.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$429,518
2023
$330,814
2022
$253,079
2021
$131,336
2020
$109,980
2019
$192,502
2018
$251,015
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$584,900
GlaxoSmithKline, LLC.
$258,426
Gilead Sciences, Inc.
$153,294
Myriad Genetic Laboratories, Inc.
$117,310
Boehringer Ingelheim Pharmaceuticals, Inc.
$110,722
EMD Serono, Inc.
$74,925
JAZZ PHARMACEUTICALS INC.
$68,687
AstraZeneca Pharmaceuticals LP
$61,638
PFIZER INC.
$52,058
Amgen Inc.
$45,769
Karyopharm Therapeutics Inc.
$37,794
Janssen Pharmaceuticals, Inc
$30,999
Janssen Biotech, Inc.
$25,793
GENZYME CORPORATION
$18,419
Foundation Medicine, Inc.
$16,057
Helsinn Therapeutics (U.S.), Inc.
$9,008
Celgene Corporation
$8,262
Kite Pharma, Inc.
$4,945
Acceleron Pharma, Inc.
$4,495
Spectrum Pharmaceuticals Inc.
$2,663
Fresenius Kabi USA, LLC
$2,550
Astellas Pharma US Inc
$1,967
Ipsen Biopharmaceuticals, Inc
$1,741
Seattle Genetics, Inc.
$1,571
R-Pharm US LLC
$1,323
Janssen Scientific Affairs, LLC
$818
BeiGene USA, Inc.
$321
Novartis Pharmaceuticals Corporation
$280
Genentech USA, Inc.
$276
PUMA BIOTECHNOLOGY, INC.
$149
SpringWorks Therapeutics, Inc.
$146
Regeneron Healthcare Solutions, Inc.
$124
Stemline Therapeutics Inc.
$123
Lilly USA, LLC
$114
Daiichi Sankyo Inc.
$77
Bayer Healthcare Pharmaceuticals Inc.
$74
Sirtex Medical Inc
$71
Seagen Inc.
$43
Takeda Pharmaceuticals U.S.A., Inc.
$38
ARRAY BIOPHARMA INC
$37
Puma Biotechnology, Inc.
$25
TAIHO ONCOLOGY, INC.
$25
Exelixis Inc.
$24
Myriad Women's Health, Inc.
$23
Incyte Corporation
$20
PharmaEssentia USA Corporation
$19
EISAI INC.
$19
Pharming Healthcare, Inc.
$19
Verity Pharmaceuticals Inc.
$19
Taiho Oncology, Inc.
$18
Secura Bio, Inc.
$15
EUSA Pharma (US) LLC
$15
Top 3 companies account for 58.7% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AKYNZEO · ALOXI · AUGTYRO · BALVERSA · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABOMETYX · CHANTIX · CYRAMZA · DARZALEX · ELIQUIS · EMPLICITI · ENDOPREDICT · ENJAYMO · ERLEADA · EndoPredict · Enhertu · FOUNDATIONONE · FOUNDATIONONE LIQUID · Fabhalta · Farydak · Folotyn · GENESIGHT · GILOTRIF · IBRANCE · IMFINZI · IMJUDO · Ixempra · JEMPERLI · JEVTANA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MYCHOICE CDX · MYRISK · NERLYNX · NINLARO · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PRECISETUMOR · PROMACTA · Padcev · Pomalyst · PreciseTumor · REBLOZYL · RUCONEST · RYBREVANT · Reblozyl · SCEMBLIX · SIR-Spheres Microspheres · SUTENT · Sylvant · TECENTRIQ · Tazverik · Tecartus · Tecentriq · Trelstar · Trodelvy · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XARELTO · XPOVIO · XTANDI · XYNTHA · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZYKADIA · Zevalin · myChoice CDx · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (98%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for hematology & oncology in TX.
Equivalent to $4,379 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
202
Per 100K population
4.2
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Pandya is a mixed practice specialist, with above-average Medicare volume (top 25% in TX), with speaking/promotional industry engagement in the top 0% of TX peers, with 18 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Pandya experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Pandya performed 25,500 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pandya receive payments from pharmaceutical companies?
Yes. Dr. Pandya received a total of $1,698,245 from 52 companies across 1,332 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pandya's costs compare to other hematology & oncology specialists in Houston?
Dr. Pandya's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pandya) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Houston
Browse hematology & oncology specialists in Houston ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology